目的探讨英夫利西单抗(Infliximab，商品名：类克，Remcidae)联合甲氨蝶呤(methotrexate，MTX)短期治疗银屑病关节炎(psoriatic arthritis，PsA)的疗效与安全性。方法对传统治疗方案[非甾体类消炎药(NSAIDs)联合MTX或其他免疫抑制剂(DMARDs)]治疗3个月以上疗效欠佳的21例患者，在0、2、6、14周时给予静脉输注Infliximab(剂量为5mg/kg体重，溶于0.9%的氯化钠注射液250ml，输液时间不少于2h)，同时给予MTX 7.5-15mg，1次/周，14周后停用Infliximab，观察患者治疗前后的临床症状、炎性实验室指标的改善情况及药物安全性。结果21例患者关节压痛数、关节肿胀数、银屑病面积和严重度指数(psoriasis area and severity index，PASI)均明显降低，同时血沉(ESR)及C反应蛋白(CRP)亦明显下降，且与治疗前相比差异有统计学意义。1例患者出现注射部位皮肤片状红肿及瘙痒，未予特殊处理后消失，其余患者均未出现明显不良反应。结论Infliximab联合MTX短期治疗银屑病关节炎有效、安全、可行。
Combination Therapy of Infliximab with Methotrexate for Twenty-one Cases with Psoriatic Arthritis
Objective To explore the efficacy and safety of Infliximab combined with methotrexate in short-term treatment of psoriatic arthritis. Methods Twenty-one patients received with 5mg phleb Infliximab which at 0, 2, 6, 14 week and 7.5-15mg oral MTX once a week. Results The swollen joint counts, tenderness joint counts and the score of PASI significantly reduced. Meanwhile the level of ESR and CRP significantly decreased in all cases(P <0.05). One patient experienced pruritus and flaky erythema at the injection site. It disappeared witnout any treatment. No severe adverse effects occurred in other patients. Conclusion The Infliximab combined with methotrexate is effective and safe in short-term treatment of psoriatic arthritis.
NETL
NSTL
万方数据
维普
